SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

ジェネリック医薬品市場調査レポート

Generic Drugs Market Research Report Information

ジェネリック医薬品市場調査レポート : タイプ（シンプルジェネリックとスーパージェネリック）、ブランド（ピュアジェネリックとブランドジェネリック）、適応症（中枢神経系（CNS）、心臓血管、泌尿器科、腫瘍学、呼吸器科、その他）、投与経路別（経口、局所、非経口薬、その他）、流通チャネル（病院薬局、小売薬局、オンライン薬局）、地域（北米、ヨーロッパ、アジア太平洋、その他の世界） - 2032年までの予測
Generic Drugs Market Research Report Information by Type (Simple Generics and Super Generics), by Brand (Pure Generic and Branded Generic), by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 2032

商品番号 : SMB-67837

出版社Market Research Future
出版年月2024年8月
ページ数160
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

Market Overview

In 2023, the generic drug market was estimated to be worth USD 410.60 billion. During the forecast period (2024-2032), the Generic Drugs Market industry is anticipated to experience a compound annual growth rate (CAGR) of 7.85%, increasing from USD 437.90 billion in 2024 to USD 874.36 billion by 2032.

2023 年のジェネリック医薬品市場は 4,106 億米ドルの価値があると推定されています。予測期間（2024年から2032年）中、ジェネリック医薬品市場業界は7.85％の年間複合成長率（CAGR）を経験し、2024年の4,379億米ドルから2032年までに8,743億6,000万米ドルに増加すると予想されます。

The growth of the global generic drug market is primarily driven by the increasing prevalence of chronic diseases worldwide and the increasing strategic initiatives of market participants. Nevertheless, it is anticipated that the global market’s expansion will be impeded by voluntary product recalls from market participants. However, it is anticipated that the market will generate profitable opportunities because of investment in research and development (R&D) for generic medications.

The global generic drug market is experiencing substantial growth because of the increasing prevalence of chronic diseases on a global scale. There is a greater demand for cost-effective treatment options due to the increasing prevalence of conditions such as cancer, neurology, cardiovascular diseases, and inflammatory diseases. Consequently, patients and healthcare providers are increasingly turning to generic medications.

Market segment insights

Simple generics and super generics comprise the Generic Drugs Market segmentation, which is determined by type.

Pure generic and branded generic comprise the Generic Drugs Market segmentation, which is determined by brand.

Central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and other indications comprise the Generic Drugs Market segmentation.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Generic Drugs market is undergoing substantial growth, which is being driven by the increasing demand for Generic Drugs in hospitals and medical settings, as well as the increasing prevalence of chronic diseases and technological advancements.

The European Generic Drugs market, which is driven by the well-established healthcare infrastructure, collaborations and partnerships between industry actors, research organizations, and healthcare providers, accounted for the second-largest market share. In addition, the Germany Generic Drugs provider is said to possess the highest market share, while the France Generic Drugs provider is expected to be the fastest-growing market in the Europe region.

The Asia-Pacific Generic Drugs market is anticipated to experience the most rapid growth from 2023 to 2032 because of the escalating healthcare expenditure and investments in research and development activities, as well as the emergence of chronic medical disorders, including cancer, diabetes, and cardiovascular diseases. Additionally, China Generic Drugs accounted for the greatest market share, while India Generic Drugs is anticipated to be the fastest-growing market in the Asia-Pacific region.

Major Players

Sun Pharmaceutical Industries Ltd. (India), Lupin Pharmaceuticals, Inc. (India), Endo International plc (Ireland), Aurobindo Pharma (India), Aspen Holdings (South Africa), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Cipla ltd. (India), Fresenius SE & Co. KGaA (Germany), and Novartis AG (Switzerland) are among the key companies in the Generic Drugs market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TYPE

3.8 DATA MODELING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE

4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS

4.3 RESTRAINTS

4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS

4.4 OPPORTUNITY

4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL

5.1.1 THREAT OF NEW ENTRANTS

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 THREAT OF SUBSTITUTES

5.1.4 BARGAINING POWER OF BUYERS

5.1.5 INTENSITY OF RIVALRY

5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

5.3 TRENDS IN DEVELOPMENTS OF INDIVIDUAL MARKETS (EU, USA, INDIA, CHINA, OTHER)

5.4 TRENDS IN THE DEVELOPMENT OF THERAPEUTIC AREAS

5.5 TRENDS IN MANUFACTURING SITES

5.6 TRENDS IN NEW TECHNOLOGICAL PLATFORMS FOR DRUGS

5.7 TRENDS IN IP

5.8 TRENDS IN QUALITY REQUIREMENTS

5.9 TRENDS IN REGULATORY REQUIREMENTS

6 GLOBAL GENERIC DRUGS MARKET, BY TYPE

6.1 OVERVIEW

6.2 SIMPLE GENERICS

6.3 SUPER GENERICS

7 GLOBAL GENERIC DRUGS MARKET, BY BRAND

7.1 OVERVIEW

7.2 PURE GENERIC

7.3 BRANDED GENERIC

8 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

8.1 OVERVIEW

8.2 CENTRAL NERVOUS SYSTEM (CNS)

8.3 CARDIOVASCULAR

8.4 UROLOGY

8.5 ONCOLOGY

8.6 RESPIRATORY

8.7 OTHERS

9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.3 TOPICAL

9.4 PARENTERAL

9.5 OTHERS

10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACY

10.3 RETAIL PHARMACY

10.4 ONLINE PHARMACY

11 GLOBAL GENERIC DRUGS MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 UK

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 INDIA

11.4.3 JAPAN

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST & AFRICA

11.5.2 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 MARKET SHARE ANALYSIS, 2022

12.3 COMPETITOR DASHBOARD

12.4 PUBLIC PLAYERS STOCK SUMMARY

12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL

12.6.2 EXPANSION

13 COMPANY PROFILES

13.1 SUN PHARMACEUTICAL INDUSTRIES LTD.

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 LUPIN PHARMACEUTICALS, INC.

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 ENDO INTERNATIONAL PLC

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 KEY STRATEGIES

13.4 AUROBINDO PHARMA

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 KEY STRATEGIES

13.5 ASPEN HOLDINGS

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCTS OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 KEY STRATEGIES

13.6 CIPLA LTD

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 NOVARTIS AG

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCTS OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 SWOT ANALYSIS

13.8.6 KEY STRATEGIES

13.9 FRESENIUS SE & CO. KGAA

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 KEY STRATEGIES

13.10 VIATRIS INC.

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 KEY STRATEGIES

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 TRENDS IN REGULATORY REQUIREMENTS

TABLE 3 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR SIMPLE GENERICS, BY REGION, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR SUPER GENERICS, BY REGION, 2019–2032 (USD BILLION)

TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR PURE GENERIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR BRANDED GENERIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019–2032 (USD BILLION)

TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019–2032 (USD BILLION)

TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019–2032 (USD BILLION)

TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2032 (USD BILLION)

TABLE 14 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019–2032 (USD BILLION)

TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019–2032 (USD BILLION)

TABLE 18 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019–2032 (USD BILLION)

TABLE 19 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019–2032 (USD BILLION)

TABLE 20 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 21 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 22 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2032 (USD BILLION)

TABLE 23 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2032 (USD BILLION)

TABLE 24 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2032 (USD BILLION)

TABLE 25 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019–2032 (USD BILLION)

TABLE 26 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 27 NORTH AMERICA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 28 NORTH AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 29 NORTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 30 NORTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 31 NORTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 32 US: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 33 US: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 34 US: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 35 US: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 36 US: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 37 CANADA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 38 CANADA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 39 CANADA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 40 CANADA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 41 CANADA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 42 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 43 EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 44 EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 45 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 46 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 47 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 48 GERMANY: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 49 GERMANY: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 50 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 51 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 52 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 53 FRANCE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 54 FRANCE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 55 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 56 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 57 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 58 UK: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 59 UK: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 60 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 61 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 62 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 63 ITALY: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 64 ITALY: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 65 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 66 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 67 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 68 SPAIN: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 69 SPAIN: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 70 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 71 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 72 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 73 REST OF EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 74 REST OF EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 75 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 76 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 77 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 78 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 79 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 80 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 81 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 82 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 83 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 84 CHINA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 85 CHINA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 86 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 87 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 88 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 89 INDIA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 90 INDIA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 91 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 92 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 93 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 94 JAPAN: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 95 JAPAN: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 96 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 97 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 98 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 99 SOUTH KOREA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 100 SOUTH KOREA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 101 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 102 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 103 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 104 AUSTRALIA: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 105 AUSTRALIA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 106 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 107 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 108 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 109 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 110 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 111 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 112 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 113 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 114 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2019–2032 (USD BILLION)

TABLE 115 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)

TABLE 116 REST OF THE WORLD: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 117 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 118 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 119 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 120 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)

TABLE 121 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 122 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 123 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 124 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 125 LATIN AMERICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD BILLION)

TABLE 126 LATIN AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019–2032 (USD BILLION)

TABLE 127 LATIN AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 128 LATIN AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 129 LATIN AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)

TABLE 130 PUBLIC PLAYERS STOCK SUMMARY

TABLE 131 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 132 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 133 EXPANSION

TABLE 134 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED

TABLE 135 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS

TABLE 136 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED

TABLE 137 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS

TABLE 138 ENDO INTERNATIONAL PLC: PRODUCT OFFERED

TABLE 139 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS

TABLE 140 AUROBINDO PHARMA: PRODUCT OFFERED

TABLE 141 AUROBINDO PHARMA: KEY DEVELOPMENTS

TABLE 142 ASPEN HOLDINGS: PRODUCT OFFERED

TABLE 143 CIPLA LTD.: PRODUCTS OFFERED

TABLE 144 CIPLA LTD.: KEY DEVELOPMENTS

TABLE 145 NOVARTIS AG: PRODUCTS OFFERED

TABLE 146 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 147 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED

TABLE 148 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS

TABLE 149 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED

TABLE 150 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS

TABLE 151 VIATRIS INC.: PRODUCT OFFERED

TABLE 152 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE

FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET

FIGURE 6 GLOBAL GENERIC DRUGS MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2022 & 2032 (USD BILLION)

FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY TYPE, 2022

FIGURE 9 GLOBAL GENERIC DRUGS MARKET, BRAND SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2022 & 2032 (USD BILLION)

FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY BRAND, 2022

FIGURE 12 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)

FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2022

FIGURE 15 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD BILLION)

FIGURE 17 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2022

FIGURE 18 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 19 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)

FIGURE 20 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2022

FIGURE 21 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)

FIGURE 22 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022

FIGURE 23 NORTH AMEICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)

FIGURE 24 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)

FIGURE 25 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 26 EUROPE MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)

FIGURE 27 EUROPE: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)

FIGURE 28 EUROPE: GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022

FIGURE 29 ASIA-PACIFIC MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)

FIGURE 30 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)

FIGURE 31 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 32 REST OF THE WORLD MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)

FIGURE 33 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)

FIGURE 34 REST OT THE WORLD: GENERIC DRUGS MARKET SHARE (%), BY REGION, 2022

FIGURE 35 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022

FIGURE 36 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET

FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 39 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 41 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 43 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 CIPLA LTD.: FINANCIAL OVERVIEW

FIGURE 45 CIPLA LTD.: SWOT ANALYSIS

FIGURE 46 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 47 NOVARTIS AG: SWOT ANALYSIS

FIGURE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 50 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 51 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

医療・医薬の最新記事8件